neuroendocrine

Cancelled

Pharma

FDA cancels adcomm for Cabometyx in neuroendocrine tumors

Exelixis’ original announcement about a planned adcomm meeting came as somewhat of a surprise given positive findings from a phase 3 trial.

Angus Liu Jan 10, 2025 9:46am

FDA

Exelixis' Cabometyx to face FDA adcomm in neuroendocrine tumors

Nov 27, 2024 11:30am

Novartis

With trial win, Novartis eyes first-line use for Lutathera

Sep 25, 2023 10:33am